Mainstream

ANI Pharmaceuticals raises 2025 guidance to $843M revenue and $7.35 EPS as Cortrophin Gel accelerates

ANI Pharmaceuticals raises 2025 guidance to $843M revenue and $7.35 EPS as Cortrophin Gel accelerates

Post ContentanipRead More

You might also be interested in reading Swiss crypto bank Sygnum secures in-principal approval in Singapore.

August 8, 2025
In Mainstream